Abbott India inks non-exclusive patent license agreement with Takeda for Vonoprazan

This license will enable Abbott to enhance access to this novel therapy to more patients across India

Abbott India Limited has signed a non-exclusive patent license agreement with Takeda Pharmaceuticals Company Limited to market and distribute "Vonoprazan" in India under the brand name "Vonefi".

Vonoprazan (PCAB or Potassium Competitive Acid Blocker) addresses severe acid related disorders like reflux esophagitis through a once daily dose. Current treatments for reflux esophagitis, a condition under the Gastroesophageal Reflux Disease (GERD) umbrella, have several limitations including the need for multiple dosing for effectiveness, especially when the condition is severe. Vonoprazan, a first-of-its kind therapy, will help make it easier for patients to comply with their treatment and manage their condition better.

This license will enable Abbott, a leader in the gut health space, to enhance access to this novel therapy to more patients across India.